Kyverna Therapeutics Unveils Detailed Positive Clinical Data for Miv-cel in SPS and gMG

summarizeSummary

Kyverna Therapeutics filed an 8-K furnishing presentation slides that detail highly positive clinical trial results for its miv-cel therapy in Stiff Person Syndrome (SPS) and generalized Myasthenia Gravis (gMG), reinforcing its potential as a first-in-class autoimmune CAR T treatment.

check_boxKey Events

• SPS Registrational Trial Success

  Miv-cel met its primary endpoint in the KYSA-8 registrational trial for Stiff Person Syndrome (SPS), showing a 46% median improvement in the Timed 25-Foot Walk (T25FW) at Week 16 (p=0.0003) and 100% of patients remaining free of immunotherapies.

• gMG Phase 2 Data Reinforcement

  Longer-term follow-up data from the KYSA-6 Phase 2 trial for generalized Myasthenia Gravis (gMG) demonstrated robust and sustained reductions in MG-ADL and QMG scores out to 52 weeks, with 100% of patients achieving clinically meaningful responses and high rates of immunotherapy-free remission.

• Strong Safety Profile

  Miv-cel exhibited a well-tolerated safety profile across both trials, with no high-grade Cytokine Release Syndrome (CRS) or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) observed.

• Advancing Pipeline

  The positive data supports Kyverna's preparations for a Biologics License Application (BLA) submission for SPS and the ongoing advancement of its Phase 3 gMG trial, positioning miv-cel as a potential first-in-class autoimmune CAR T therapy.

auto_awesomeAnalysis

This 8-K provides the comprehensive clinical data supporting the positive top-line results for miv-cel in both the registrational KYSA-8 trial for Stiff Person Syndrome (SPS) and the Phase 2 KYSA-6 trial for generalized Myasthenia Gravis (gMG), which were initially announced on April 20 and April 21, 2026. The detailed presentation highlights that miv-cel met its primary endpoint in SPS with significant improvements in mobility and disability, and demonstrated robust, sustained efficacy in gMG, including 100% clinically meaningful response and high rates of immunotherapy-free remission. The well-tolerated safety profile across both indications further strengthens the drug's profile, positioning Kyverna for a potential BLA submission for SPS and advancement of its Phase 3 gMG trial. This detailed disclosure provides investors with critical evidence of the drug's transformative potential in autoimmune diseases.